SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549


                                    FORM 8-K

                                 CURRENT REPORT


     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

       Date of Report (Date of earliest event reported): December 1, 2005

                        Commission File Number: 000-49620

                                  Cobalis Corp.
                                  -------------
             (Exact name of registrant as specified in its charter)

Nevada                                                                91-1868007
------                                                                ----------
(State or other jurisdiction of             (I.R.S. Employer Identification No.)
incorporation or organization)

2445 McCabe Way, Suite 150, Irvine, CA                                     92614
---------------------------------------                                    -----
(Address of principal executive offices)                              (Zip Code)



                                 (949) 757-0001
                                 --------------
              (Registrant's Telephone Number, Including Area Code)


Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

|_| Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)

|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)

|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))

|_| Pre commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))


<PAGE>



ITEM 5.02 APPOINTMENT OF PRINCIPAL OFFICERS
-------------------------------------------

On December 1, 2005, Cobalis Corp., a Nevada corporation (the "Registrant")
announced that it had hired Thomas Stankovich as its new Executive Vice
President, Chief Financial Officer effective immediately. Before joining the
Registrant, Mr. Stankovich, 45, previously served as Senior Vice President and
Chief Financial Officer of MP Biomedicals from 2003 to the present. From 2001 to
2003, he served as Senior Vice President and Chief Financial Officer for
Ribapharm, Inc. (now part of Valeant Pharmaceuticals International). From 1986
to 2001, Mr. Stankovich has served in various executive financial management
positions for ICN Pharmaceuticals, Inc. (now renamed Valeant Pharmaceuticals
International) including Vice President, Chief Financial Officer for ICN
International A.G., and Vice President and Controller for ICN Europe. Mr.
Stankovich holds Bachelor of Science degrees in both accounting and finance from
California State University, Northridge, which he earned in 1984. Mr. Stankovich
is not an officer or director of any other reporting company, nor is he a family
member of any current officer or director of the Registrant.

The Registrant has entered into an employment contract with Mr. Stankovich which
provides for Mr. Stankovich to serve as the Registrant's Chief Financial Officer
and as Executive Vice President for a term of three years, renewable annually,
for compensation of a base salary $200,000 per year and other employee benefits,
plus a signing bonus of shares of the Registrant's common stock, and stock
options/warrants to purchase shares of the Registrant's common stock at $1.75
per share vesting over a period of two years.

ITEM 8.01 OTHER EVENTS.
------------------------

On December 1, 2005, the Registrant made the announcement contained in the
attached press release.

A copy of the press release is attached hereto as Exhibit 99.1 and is
incorporated herein by reference. Except for historical information contained
herein, the matters set forth in this report are forward-looking statements. The
forward-looking statements set forth above involve a number of risks and
uncertainties that could cause actual results to differ materially from any such
statement, including the risks and uncertainties discussed in the Registrant's
Safe Harbor Compliance Statement for Forward-looking Statements included in the
Registrant's recent filings, including Forms 8-K, 10-KSB and 10-QSB, with the
Securities and Exchange Commission.

ITEM 9.01 EXHIBITS.
--------------------

The following exhibits are filed with this report on Form 8-K.

Exhibit Number         Exhibit
--------------         ----------------
99.1                   Press Release




<PAGE>




                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.



                                              Cobalis Corp.

December  6, 2005                         By: /s/ Chaslav Radovich
                                              ------------------------------
                                              Chaslav Radovich, President
[{"type": "8-K", "sequence": "1", "filename": "cobalis_8k.txt", "secsgml_size_bytes": 5134}]
{"company-data": {"conformed-name": "Cobalis Corp", "cik": "0001166414", "assigned-sic": "2834", "irs-number": "911868007", "state-of-incorporation": "NV"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-49620", "film-number": "051247802"}, "business-address": {"street1": "2445 MCCABE WAY, SUITE 150", "city": "IRVINE", "state": "CA", "zip": "92614", "phone": "949-757-0001"}, "mail-address": {"street1": "2445 MCCABE WAY, SUITE 150", "city": "IRVINE", "state": "CA", "zip": "92614"}, "former-company": [{"former-conformed-name": "BIOGENTECH CORP", "date-changed": "20030625"}, {"former-conformed-name": "TOGS FOR TYKES INC", "date-changed": "20020201"}]}
SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

       Date of Report (Date of earliest event reported): December 1, 2005

                        Commission File Number: 000-49620

                                  Cobalis Corp.
                                  -------------
             (Exact name of registrant as specified in its charter)

Nevada                                                                91-1868007
------                                                                ----------
(State or other jurisdiction of             (I.R.S. Employer Identification No.)
incorporation or organization)

2445 McCabe Way, Suite 150, Irvine, CA                                     92614
---------------------------------------                                    -----
(Address of principal executive offices)                              (Zip Code)

                                 (949) 757-0001
                                 --------------
              (Registrant's Telephone Number, Including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

|_| Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)

|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)

|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))

|_| Pre commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
ITEM 5.02 APPOINTMENT OF PRINCIPAL OFFICERS
-------------------------------------------

On December 1, 2005, Cobalis Corp., a Nevada corporation (the "Registrant")
announced that it had hired Thomas Stankovich as its new Executive Vice
President, Chief Financial Officer effective immediately. Before joining the
Registrant, Mr. Stankovich, 45, previously served as Senior Vice President and
Chief Financial Officer of MP Biomedicals from 2003 to the present. From 2001 to
2003, he served as Senior Vice President and Chief Financial Officer for
Ribapharm, Inc. (now part of Valeant Pharmaceuticals International). From 1986
to 2001, Mr. Stankovich has served in various executive financial management
positions for ICN Pharmaceuticals, Inc. (now renamed Valeant Pharmaceuticals
International) including Vice President, Chief Financial Officer for ICN
International A.G., and Vice President and Controller for ICN Europe. Mr.
Stankovich holds Bachelor of Science degrees in both accounting and finance from
California State University, Northridge, which he earned in 1984. Mr. Stankovich
is not an officer or director of any other reporting company, nor is he a family
member of any current officer or director of the Registrant.

The Registrant has entered into an employment contract with Mr. Stankovich which
provides for Mr. Stankovich to serve as the Registrant's Chief Financial Officer
and as Executive Vice President for a term of three years, renewable annually,
for compensation of a base salary $200,000 per year and other employee benefits,
plus a signing bonus of shares of the Registrant's common stock, and stock
options/warrants to purchase shares of the Registrant's common stock at $1.75
per share vesting over a period of two years.

ITEM 8.01 OTHER EVENTS.
------------------------

On December 1, 2005, the Registrant made the announcement contained in the
attached press release.

A copy of the press release is attached hereto as Exhibit 99.1 and is
incorporated herein by reference. Except for historical information contained
herein, the matters set forth in this report are forward-looking statements. The
forward-looking statements set forth above involve a number of risks and
uncertainties that could cause actual results to differ materially from any such
statement, including the risks and uncertainties discussed in the Registrant's
Safe Harbor Compliance Statement for Forward-looking Statements included in the
Registrant's recent filings, including Forms 8-K, 10-KSB and 10-QSB, with the
Securities and Exchange Commission.

ITEM 9.01 EXHIBITS.
--------------------

The following exhibits are filed with this report on Form 8-K.

Exhibit Number         Exhibit
--------------         ----------------
99.1                   Press Release
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.

                                              Cobalis Corp.

December  6, 2005                         By: /s/ Chaslav Radovich
                                              ------------------------------
                                              Chaslav Radovich, President